CompletedEUCTR 2008-007483-42
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
This historical record does not confirm current site availability.
Historical research recordMultiple countriesBipolarity
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with type I bipolarity. Other eligibility criteria applied.
- Listed locations
- Czechia · France and 3 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 651
- Sponsor
- Sunovion Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, Czechia, Germany, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2008-007483-42
- Official title
Show the full official title
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
Get this study by email
Recruitment & locations
CompletedCzechia · France · Germany
2 more locations
- Lithuania
- Slovakia
Questions about this study
Who is behind this study?
The study sponsor is Sunovion Pharmaceuticals Inc.
Who was this study for?
This study was for people with type I bipolarity. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...